| Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report M Brunet, T Van Gelder, A Åsberg, V Haufroid, DA Hesselink, L Langman, ... Therapeutic drug monitoring 41 (3), 261-307, 2019 | 574 | 2019 |
| A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients L Elens, R Bouamar, DA Hesselink, V Haufroid, IP van der Heiden, ... Clinical chemistry 57 (11), 1574-1583, 2011 | 299 | 2011 |
| The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation DA Hesselink, R Bouamar, L Elens, RHN Van Schaik, T Van Gelder Clinical pharmacokinetics 53, 123-139, 2014 | 288 | 2014 |
| CYP3A4*22: Promising Newly Identified CYP3A4 Variant Allele for Personalizing Pharmacotherapy L Elens, T Van Gelder, DA Hesselink, V Haufroid, RHN Van Schaik Pharmacogenomics 14 (1), 47-62, 2013 | 262 | 2013 |
| CYP3A5 and ABCB1 Polymorphisms and Tacrolimus Pharmacokinetics in Renal Transplant Candidates: Guidelines from an Experimental Study V Haufroid, P Wallemacq, V VanKerckhove, L Elens, M De Meyer, ... American journal of transplantation 6 (11), 2706-2713, 2006 | 226 | 2006 |
| Effect of a New Functional CYP3A4 Polymorphism on Calcineurin Inhibitors‘ Dose Requirements and Trough Blood Levels in Stable Renal Transplant Patients L Elens, RH Van Schaik, N Panin, M De Meyer, P Wallemacq, D Lison, ... Pharmacogenomics 12 (10), 1383-1396, 2011 | 202 | 2011 |
| CYP3A5 and ABCB1 Polymorphisms Influence Tacrolimus Concentrations in Peripheral Blood Mononuclear Cells After Renal Transplantation A Capron, M Mourad, M De Meyer, L De Pauw, DC Eddour, D Latinne, ... Pharmacogenomics 11 (5), 703-714, 2010 | 156 | 2010 |
| Personalized therapy for mycophenolate: consensus report by the international association of therapeutic drug monitoring and clinical toxicology S Bergan, M Brunet, DA Hesselink, KL Johnson-Davis, PK Kunicki, ... Therapeutic drug monitoring 43 (2), 150-200, 2021 | 140 | 2021 |
| 1199G> A and 2677G> T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation L Elens, A Capron, V Van Kerckhove, J Lerut, M Mourad, D Lison, ... Pharmacogenetics and genomics 17 (10), 873-883, 2007 | 133 | 2007 |
| Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study L Elens, ML Becker, V Haufroid, A Hofman, LE Visser, AG Uitterlinden, ... Pharmacogenetics and genomics 21 (12), 861-866, 2011 | 132 | 2011 |
| CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity AJM de Graan, L Elens, JA Sprowl, A Sparreboom, LE Friberg, ... Clinical Cancer Research 19 (12), 3316-3324, 2013 | 116 | 2013 |
| Impact of POR* 28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients L Elens, DA Hesselink, R Bouamar, K Budde, JW de Fijter, M De Meyer, ... Therapeutic drug monitoring 36 (1), 71-79, 2014 | 113 | 2014 |
| Impact of CYP3A4* 22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines L Elens, A Capron, RHN van Schaik, M De Meyer, L De Pauw, DC Eddour, ... Therapeutic drug monitoring 35 (5), 608-616, 2013 | 111 | 2013 |
| The new CYP3A4 intron 6 C> T polymorphism (CYP3A4* 22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney … L Elens, R Bouamar, DA Hesselink, V Haufroid, T van Gelder, ... Pharmacogenetics and genomics 22 (5), 373-380, 2012 | 108 | 2012 |
| Influence of polymorphic OATP1B-type carriers on the disposition of docetaxel AJM de Graan, CS Lancaster, A Obaidat, B Hagenbuch, L Elens, ... Clinical Cancer Research 18 (16), 4433-4440, 2012 | 99 | 2012 |
| A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach F Andreu, H Colom, L Elens, T van Gelder, RHN van Schaik, ... Clinical pharmacokinetics 56, 963-975, 2017 | 98 | 2017 |
| A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients LM Andrews, DA Hesselink, RHN Van Schaik, T van Gelder, JW De Fijter, ... British journal of clinical pharmacology 85 (3), 601-615, 2019 | 90 | 2019 |
| Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study AL Sennesael, AS Larock, J Douxfils, L Elens, G Stillemans, M Wiesen, ... Thrombosis journal 16, 1-8, 2018 | 88 | 2018 |
| The CYP3A4* 22 C> T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients H De Jonge, L Elens, H De Loor, RH Van Schaik, DRJ Kuypers The pharmacogenomics journal 15 (2), 144-152, 2015 | 78 | 2015 |
| Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug–drug interactions L Elens, LJ Langman, DA Hesselink, S Bergan, DJAR Moes, M Molinaro, ... Therapeutic drug monitoring 42 (3), 360-368, 2020 | 76 | 2020 |
